Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/11/2018
SIETES contiene 92578 citas

 
 
 1 a 20 de 102 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Goldenberg JZ, Mertz D, Johnston BC. Probiotics to prevent Clostridium difficile Infection in patients receiving antibiotics. JAMA 2018;320:7 de agosto. [Ref.ID 102829]
3. Cita con resumen
Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 2018;378:2506-16. [Ref.ID 102735]
5. Cita con resumen
Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017;177:1308-15. [Ref.ID 102042]
6.Enlace a cita original Cita con resumen
Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection. A systematic review and meta-analysis. JAMA Intern Med 2017;177:784-91. [Ref.ID 101506]
7. Cita con resumen
McDonald EG, Milligan J, Frenette C, Lee TD. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 2015;175:784-91. [Ref.ID 99028]
8. Cita con resumen
9. Cita con resumen
Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Méek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-34. [Ref.ID 98811]
10.Tiene citas relacionadas Cita con resumen
Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Buttò V, Ferrucci L, Bandinelli S, Abbatecola AM, Spazzafumo L, Lattanzio F. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013;173:518-23. [Ref.ID 95257]
11. Cita con resumen
Suissa D, Delaney JAC, Dial S, Brassard P. Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease. Br J Clin Pharmacol 2012;74:370-5. [Ref.ID 93520]
12. Cita con resumen
Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. The American Journal of Gastroenterology 2012;107:1001-10. [Ref.ID 92868]
13. Cita con resumen
Kuehn BM. C difficile plateaus. JAMA 2012;307:1243. [Ref.ID 92570]
15. Cita con resumen
Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, Slymen D, Lederman ER. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011;53:1173-8. [Ref.ID 91843]
16. Cita con resumen
Anónimo. Fidaxomicin (Dificid) for Clostridium difficile infection. Med Lett Drugs Ther 2011;53:73-4. [Ref.ID 91500]
17. Cita con resumen
Oake N, Taljaard M, van Walraven C, Wilson K, Roth V, Forster AJ. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med 2010;170:1804-10. [Ref.ID 89632]
18. Cita con resumen
Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010;303:2035-42. [Ref.ID 88508]
19. Cita con resumen
Voelker R. Increased Clostridium difficile virulence demands new treatment approach. JAMA 2010;303:2017-9. [Ref.ID 88506]
20. Cita con resumen
Howell D, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90. [Ref.ID 88368]
Seleccionar todas
 
 1 a 20 de 102 siguiente >>